Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib Monotherapy in Relapsed Small Cell Lung Cancer
NCT02593019Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adavosertib in small cell lung cancer (SCLC), sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate at 24 weeks. Started Dec 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02593019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593019.